PD-L1 antibody (AA 181-230)

Catalog No. ABIN7227724

This Rabbit Polyclonal antibody specifically detects PD-L1 in ELISA and IHC (p). It exhibits reactivity toward Human.

Quick Overview for PD-L1 antibody (AA 181-230) (ABIN7227724)

Target: PD-L1 (CD274 (PD-L1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This PD-L1 antibody is un-conjugated

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-PD-L1 Antibody

Binding Specificity: AA 181-230

Purpose: CD274 Polyclonal Antibody

Specificity: The antibody detects endogenous levels of CD274

Purification: The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen

Immunogen: Synthesized peptide derived from part region of human CD274 protein at AA range: 181-230

Isotype: IgG

Application Details

Application Notes: Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-P (1:50-1:200), ELISA (1:10000-1:20000).

Comment:

Primary Antibody

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, containing 0.02 % Sodium Azide as preservative and 50 % Glycerol as stabilizer.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Stable for one year at -20°C from date of shipment. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquot to avoid repeated freezing and thawing.

Target Details for PD-L1

Target: PD-L1 (CD274 (PD-L1))

Alternative Name: CD274

Background: Rabbit Anti-CD274 Polyclonal Antibody,Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD antigen CD274,CD274, also commonly referred to as PDL1, is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. PD1 expression has been observed in a variety of cancers including melanoma and non-small cell lung cancer. The interaction of PD1/PDL1 is hypothesized to be a possible mechanism for the tumor to escape immune response. A number of checkpoint blockade inhibitors including pembrolizumab and nivolumab have been developed that target the PD1/PDL1 interaction in order to allow T-cells to recognize tumor cells without being deactivated by the tumor.,CD274

Gene ID: 29126

UniProt: Q9NZQ7

Pathways: Cancer Immune Checkpoints